Loading...
XWAR
RVU
Market cap180mUSD
Jun 11, Last price  
28.80PLN
1D
-5.57%
1Q
52.54%
Jan 2017
-0.31%
IPO
424.59%
Name

Ryvu Therapeutics SA

Chart & Performance

D1W1MN
P/E
—
P/S
8.54
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.68%
Rev. gr., 5y
12.87%
Revenues
78m
+66.38%
8,846,6289,018,0589,419,84313,153,06828,864,75841,028,64148,133,12787,820,45977,205,57142,567,16315,414,30811,186,40238,804,00046,860,00077,968,000
Net income
-111m
L+20.98%
00005,850,1266,269,8112,720,2116,406,932-106,320-35,998,690-31,687,587-77,534,706-83,782,000-92,112,000-111,435,000
CFO
-129m
L+62.79%
000-694,940,040-4,902,078-16,429,766-6,280,11210,981,780-36,416,5860-10,635,891-57,867,88221,319,000-79,535,000-129,479,000

Profile

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
URL
https://ryvu.com/
IPO date
Jul 14, 2011
Employees
215
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
77,968
66.38%
46,860
20.76%
38,804
246.89%
Cost of revenue
19,580
17,554
48,955
Unusual Expense (Income)
NOPBT
58,388
29,306
(10,151)
NOPBT Margin
74.89%
62.54%
Operating Taxes
297
4,587
Tax Rate
0.51%
NOPAT
58,091
29,306
(14,738)
Net income
(111,435)
20.98%
(92,112)
9.94%
(83,782)
8.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
250,284
BB yield
Debt
Debt current
791
541
1,903
Long-term debt
76,612
1,144
2,759
Deferred revenue
42,738
75,803
Other long-term liabilities
9,504
73,542
10,103
Net debt
(99,444)
(248,891)
(117,730)
Cash flow
Cash from operating activities
(129,479)
(79,535)
21,319
CAPEX
(5,903)
(8,579)
(9,287)
Cash from investing activities
137,165
(200,654)
690
Cash from financing activities
94,209
240,833
(2,455)
FCF
62,911
257,073
(228,877)
Balance
Cash
225,399
233,672
101,917
Long term investments
(48,552)
16,904
20,475
Excess cash
172,949
248,233
120,452
Stockholders' equity
(102,196)
(260,156)
99,445
Invested Capital
373,836
594,196
331,629
ROIC
12.00%
6.33%
ROCE
21.49%
8.77%
EV
Common stock shares outstanding
23,120
22,898
18,335
Price
Market cap
EV
EBITDA
68,883
40,277
2,749
EV/EBITDA
Interest
3,808
97
1,089
Interest/NOPBT
6.52%
0.33%